Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Respiratory Research
|
August 27, 2016
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations
U Peretti, R Ferrara, S Pilotto, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
September 10, 2004
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules
E Terzoli, C Nisticò, A Fabi, et al.
European Review for Medical and Pharmacological Sciences
|
August 6, 2019
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors
R Iezzi, A R Larici, A Posa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2012
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
E Bria, G De Manzoni, S Beghelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Scientific Reports
|
March 11, 2016
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis
E Bria, S Pilotto, M Simbolo, et al.
Clinical Colorectal Cancer
|
July 5, 2024
Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)
M A Calegari, I V Zurlo, E Dell'Aquila, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
British Journal of Cancer
|
June 1, 2006
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
G Ferretti, E Bria, D Giannarelli, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Respiratory Research
|
August 27, 2016
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations
U Peretti, R Ferrara, S Pilotto, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
September 10, 2004
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules
E Terzoli, C Nisticò, A Fabi, et al.
European Review for Medical and Pharmacological Sciences
|
August 6, 2019
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors
R Iezzi, A R Larici, A Posa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2012
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
E Bria, G De Manzoni, S Beghelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Scientific Reports
|
March 11, 2016
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis
E Bria, S Pilotto, M Simbolo, et al.
Clinical Colorectal Cancer
|
July 5, 2024
Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)
M A Calegari, I V Zurlo, E Dell'Aquila, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
British Journal of Cancer
|
June 1, 2006
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
G Ferretti, E Bria, D Giannarelli, et al.
Page
of 6